Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure in which the heart muscle is weakened, but the left ventricular ejection fraction (LVEF) is 50% or higher. The LVEF is a measure of how much blood the left ventricle pumps out with each contraction.

Bisoprolol fumarate (Zebeta) is a beta-blocker that is used to treat a number of cardiovascular conditions, including heart failure with reduced ejection fraction (HFrEF). Beta-blockers work by blocking the effects of the hormones adrenaline and noradrenaline on the heart. This can help to slow the heart rate, reduce blood pressure, and improve the heart's ability to pump blood.

Research on Bisoprolol Fumarate and HFpEF

Research on the use of bisoprolol fumarate in HFpEF is limited, but some studies have shown that it can be beneficial for patients with this condition. For example, a study published in the Journal of the American Heart Association in 2022 found that bisoprolol fumarate was effective in reducing the risk of hospitalization and death in patients with HFpEF.

Another study, published in the journal Circulation: Heart Failure in 2021, found that bisoprolol fumarate was effective in improving exercise tolerance and quality of life in patients with HFpEF.

How Bisoprolol Fumarate Can Help Patients with HFpEF

Bisoprolol fumarate can help patients with HFpEF in a number of ways, including:

1. Reducing the heart rate and workload: Bisoprolol fumarate can help to slow the heart rate and reduce the workload on the heart. This can improve the heart's ability to pump blood and reduce symptoms of heart failure, such as shortness of breath and fatigue.

2. Lowering blood pressure: Bisoprolol fumarate can also help to lower blood pressure. This can reduce the risk of complications such as stroke and heart attack.

3. Improving exercise tolerance: Bisoprolol fumarate can help to improve exercise tolerance in patients with HFpEF. This is because it can increase the heart's efficiency and reduce the amount of oxygen that the heart needs to pump blood.

4. Improving quality of life: Bisoprolol fumarate can help to improve the quality of life of patients with HFpEF by reducing symptoms, improving exercise tolerance, and allowing patients to live more active and fulfilling lives.

Conclusion

Bisoprolol fumarate is a promising treatment option for patients with HFpEF. It has been shown to be effective in reducing the risk of hospitalization and death, improving exercise tolerance, and improving quality of life in patients with this condition.

If you have HFpEF, talk to your doctor about whether bisoprolol fumarate is right for you.